Showing 781-790 of 3017 results for "".
Skincare on Tap
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/skincare-on-tap/23791/Co-Founder William Giandoni discusses Skintap’s business model.DERM2020 Attendee Reaction: TJ Chao, MPAS, PA-C
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-attendee-reaction-tj-chao-mpas-pa-c/19846/TJ Chao, MPAS, PA-C from Atlanta, GA shares his thoughts on participating in DERM2020.Advances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futUpdates in Pediatric Dermatology
https://practicaldermatology.com/topics/psoriasis/updates-in-pediatric-dermatology/19733/2019 was bookended by the release of new treatment guidelines for pediatric skin disorders. Sheila Fallon Friedlander, MD, gives an overview of these developments and other hot topics in pediatric dermatology.DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourStirring the Pot: Cannabinoids and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/stirring-the-pot-cannabinoids-and-atopic-dermatitis/20565/Cannabinoids are a diverse group of compounds that may hold significant therapeutic capabilities applicable to many areas of medicine, including dermatology.Panel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcDermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moUpdate on Pediatric Psoriasis
https://practicaldermatology.com/columns/clinical-focus-1/update-on-pediatric-psoriasis/23358/New guidelines and new treatments seek to dramatically improve lives of children with psoriasis.Emerging Technology: A Look at Nano-Pulse Stimulation
https://practicaldermatology.com/topics/skin-cancer-photoprotection/emerging-technology-a-look-at-nano-pulse-stimulation/23336/NPS is emerging as a novel technology platform for general and aesthetic dermatology.